Review article: Is Helicobacter pylori status relevant in the management of GORD?

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 14, Issue 3, 2000, Pages 31-42

  Vigneri, S ^a   Termini, R ^a   Savarino, V ^a   Pace, F ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; STOMACH SECRETION INHIBITOR;

ACID SECRETION; ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER RISK; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE SEVERITY; EATING HABIT; ERADICATION THERAPY; GASTRITIS; GASTROESOPHAGEAL REFLUX; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SMOKING; WEIGHT GAIN;

ANIMAL; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN;

EID: 0033783443     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (100)

1. Prevalence of Helicobacter pylori infection in 190 control subjects and 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's mucosa
2. Reflux oesophagitis and Helicobacter pylori infection in elderly patients
3. Low prevalence of Helicobacter pylori infection in patients with reflux esophagitis
4. Helicobacter pylori prevalence in reflux esophagitis - A case control study
5. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with proton pump inhibitor Pantoprazole
6. Review article: Helicobacter pylori and gastroesophageal reflux disease. Clinical implications and management
7. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease
8. Helicobacter pylori and gastro-oesophageal reflux disease. A prospective study
9. Treatment of ulcerative reflux oesophagitis with colloidal bismuth subcitrate in combination with cimetidine
10. Prevalence of Campylobacter pylori in esophagitis, gastritis and duodenal ulcer
11. Campylobacter pylori and reflux oesophagitis
12. Non-steroidal anti-inflammatory drugs, hiatus hernia and Helicobacter pylori in patients with oesophageal ulceration
13. Helicobacter pylori: Has it a part in the lesion of the gastroesophageal reflux?
14. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's mucosa
15. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
16. Epidemiology of H. pylori in Western countries
17. The increasing frequency of adenocarcinoma of the esophagus
18. Opposing time trends of peptic ulcer and reflux disease
19. The seroprevalence of CagA positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease
20. An inverse correlation between CagA+ strains of Helicobacter pylori infection and risk of oesophageal and gastric cardia adenocarcinoma
21. Virulent Helicobacter pylori in patients with gastric and oesophageal adenocarcinoma
22. Effect of Campylobacter protein on acid secretion by parietal cell
23. Urea hydrolysis in Helicobacter pylori infection
24. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis
25. The prevalence of oesophagitis in patients with duodenal ulcer after eradication of Helicobacter pylori infection: One year follow up
26. Relationship between lower esophageal sphincter pressure and serum gastrin concentration in Zollinger-Ellison syndrome and other clinical settings
27. Campylobacter pylori and duodenal ulcers: The gastrin link
28. Inappropriate hypergastrinemia in asymptomatic healthy subjects infected with Helicobacter pylori infection
29. Plasma gastrin, daytime intragastric pH and nocturnal acid output before and at I and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects
30. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease
31. The degree of hypergastrinemia induced by Helicobacter pylori is the same in duodenal ulcer patients and healthy volunteers
32. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer
33. Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin
34. Campylobacter pylori is not associated with gastroparesis
35. Gastrointestinal motility in patients with non-ulcer dyspepsia: A role for Helicobacter pylori infection?
36. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia
37. The association of histological gastritis with gastroesophageal reflux and delayed gastric emptying
38. H. pylori and CagA: Relationships with gastric cancer, duodenal ulcer and reflux esophagitis and its complications
39. The gastric cardia in Helicobacter pylori infection
40. Prevalence and pattern of Helicobacter pylori gastritis in the gastric cardia
41. Transient lower esophageal sphincter relaxation
42. Deleterious effects of prostaglandin E2 in reflux oesophagitis
43. Helicobacter pylori stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line
44. Helicobacter pylori reinfection with identical organisms: Transmission by the patients' spouses
45. Long-term consequences of Helicobacter pylori eradication: Clinical aspects
46. Reflux esophagitis: A complication of Helicobacter pylori (BP) eradication therapy
47. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux oesophagitis
48. Increase of gastric acid secretion after H. pylori eradication caused the development of reflux esophagitis
49. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux
50. Twenty-four hour esophageal pHmetry in patients with non-ulcer dyspepsia is unchanged after H. pylori eradication
51. Omeprazole therapy modifies the gastric localization of Helicobacter pylori
52. The effects of omeprazole long-term treatment for duodenal ulcer on Helicobacter pylori
53. Omeprazole long-term treatment for duodenal ulcer effects on the gastric distribution of Helicobacter pylori
54. Helicobacter pylori and chronic gastritis during omeprazole long-term treatment for duodenal ulcer
55. Long-term sequelae of Helicobacter pylori gastritis
56. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole
57. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication
58. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole
59. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia
60. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease
61. Antral Helicobacter pylori like organisms in different states of gastric acid secretion
62. Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics
63. Review article: The development of atrophic gastritis, Helicobacter pylori and the effects of acid suppressive therapy
64. Lack of effect of acid suppression therapy on gastric atrophy
65. Long term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis
66. H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients
67. Gastritis. Helicobacter pylori. and proton pump inhibitors
68. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis
69. Contribution of BLA-DQA gene to host's response against Helicobacter pylori
70. Local acid production and Helicobacter pylori: A unifying hypothesis of gastroduodenal disease
71. Helicobacter pylori and gastric acid: Biological and therapeutic implications
72. The gastric transitional zones: Neglected links between gastroduodenal pathology and Helicobacter ecology
73. The effect of environmental pH on the proton motive force of Helicobacter pylori
74. Long-term acid control and proton pump inhibitors: Interactions and safety issues in perspectives
75. Effect of H. pylori status on intragastric pH during treatment with omeprazole
76. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole
77. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
78. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine
79. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer
80. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole
81. Omeprazole: Helicobacter pylori makes thee greater yet
82. The reversible H/K AT-P-ase antagonist By841 is more effective in elevating gastric pH in Helicobacter pylori positive than in Hp negative volunteers
83. Intragastric pH during treatment with omeprazole: Role of Helicobacter pylori and H. pylori-associated gastritis
84. Eleven years experience of continuous maintenance treatment with omeprazole in GERD patients
85. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy
86. Rebound hypersecretion after omeprazole and its relation on treatment acid suppression and Helicobacter pylori status
87. Omeprazole produces parietal cell hypertrophy and hyperplasia in humans
88. Guidelines for the treatment of Helicobacter pylori infection
89. Chronic peptic ulcer of the oesophagus and 'oesophagitis'
90. Barrett's esophagus and adenocarcinoma
91. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
92. Prevalence and significance of Helicobacter pylori in patients with Barrett's esophagus
93. Examination of tissue distribution of Helicobacter pylori within columnar-lined esophagus
94. Barrett's esophagus: The long and short of it
95. Inflammation and intestinal metaplasia of the gastric cardia: The role of gastroesophageal reflux and H. pylori infection
96. Helicobacter infection and adenocarcinoma arising in Barrett's esophagus
97. Helicobacter pylori colonization of Barrett's esophagus and its progression to cancer
98. Corpus gastritis is protective against reflux oesophagitis
99. Helicobacter pylori and gastroesophageal reflux disease: The bug may not be all bad
100. Not all Helicobacter pylori strains are creted equal: Should all be eliminated?